Isigaba 2A Ukwelashwa Komdlavuza wamaphaphu 2026: Idatha entsha ye-ELCC ku-Neo-Adjuvant Therapy 

Isigaba 2A sokwelashwa komdlavuza wamaphaphu ngo-2026 iye yashintsha kakhulu, yasuka ezindleleni zokuhlinza kuphela yaya kumasu ezinto eziningi ezihlanganisa i-neo-adjuvant therapy. Imihlahlandlela yamanje igcizelela ukuhlanganisa i-immunotherapy kanye ne-chemotherapy ngaphambi kokuhlinzwa ukuze kuthuthukiswe amazinga okuphendula okuphelele kwe-pathological (pCR) nokuphila isikhathi eside. Idatha yakamuva evela ku-European Lung Cancer Congress (ELCC) yango-2026 igqamisa ukuthi imishanguzo emisha, okuhlanganisa i-dual-checkpoint inhibitors kanye ne-immunogenic radiotherapy, ichaza kabusha imiphumela yomdlavuza wamaphaphu ongewona omncane (NSCLC) ongase utholakale.

Ukuqonda Isigaba 2A Umdlavuza Ongewona Omncane Wengqamuzana Wamaphaphu

I-Stage 2A NSCLC imele isikhathi esibucayi ekulawulweni komdlavuza wamaphaphu lapho isimila sitholakala endaweni kodwa sinengozi yesifo se-micrometastatic. Ngokomlando, ukuhlinza ngokushesha kwakuyizinga lokunakekelwa. Kodwa-ke, i-oncology yesimanje iyaqaphela ukuthi ukwelashwa okuhlelekile okwenziwa ngaphambi kokuhlinzwa kungaqeda izifo ezingabonakali ezisakazeka kusenesikhathi.

Incazelo yeSigaba 2A ngokuvamile ihilela izimila ezinkulu kuno-3 cm kodwa ezingadluli ku-4 cm ngaphandle kokubandakanyeka kwe-lymph node, noma izimila ezincane ezinokuhlaselwa okuthile kwasendaweni. Isiteji esinembile sibalulekile, njengoba sibeka ukufaneleka kwezivumelwano ze-neo-adjuvant.

• Usayizi Wethumba: Ngokuvamile phakathi kuka-3 cm no-4 cm ekuhlukaniseni kwe-T2a N0 M0.
• Isimo se-Lymph Node: Imvamisa ayikho i-regional lymph node metastasis (N0), nakuba ukubandakanyeka okuncane kuyinkinga.
• Ukukhishwa kabusha: Iziguli zibhekwa njengamakhandidethi okususwa ngokuphelele kokuhlinzwa (ukukhishwa kabusha kwe-R0).

Inhloso yokwelashwa akukhona nje ukususwa kwesimila kodwa ukuqinisekisa ukusinda kwesikhathi eside kwesifo (DFS) kanye nokusinda okuphelele (OS). Ukushintshela ekwelashweni kwe-systemic kwangaphambi kokusebenza kuhlose ukwehlisa isimila, ukwenza ukuhlinzwa kube lula futhi kusebenze kakhudlwana.

Ukushintsha kusuka ku-Adjuvant kuye ku-Neo-Adjuvant Therapy

Emashumini eminyaka, i-adjuvant chemotherapy (enikezwa ngemva kokuhlinzwa) kwakuyinto evamile. Nakuba inikeza izinzuzo ezinesizotha, ukuthobela ngokuvamile kwakungekuhle ngenxa yezinkinga zokululama ngemva kokuhlinzwa. I-Neo-adjuvant therapy, enikezwa ngaphambi kokuhlinzwa, ibhekana nalokhu ngokwelapha isiguli sisaphilile.

Ukuhlolwa komtholampilo kwakamuva kubonise ukuthi izindlela ze-neo-adjuvant zikhiqiza amanani aphezulu e-pCR uma kuqhathaniswa nezilungiselelo ze-adjuvant. Ukuzuza i-pCR, lapho kungekho amangqamuzana omdlavuza asebenzayo ahlala esibonelweni sokuhlinzwa, kuhlotshaniswa kakhulu nemiphumela yesikhathi eside ethuthukisiwe. Lokhu kushintsha kwepharadigm kumaphakathi nezwe lokwelapha lika-2026.

Ngaphezu kwalokho, ukwelashwa kwe-neo-adjuvant kuvumela odokotela ukuthi bahlole impendulo yesimila ngesikhathi sangempela. Uma isimila singaphenduli ohlelweni lokuqala, ukwelashwa kungalungiswa ngaphambi kokuhlinzwa, ukugwema izinqubo eziyize ezimweni zezifo ezinolaka.

2026 Ukuphumelela kwe-ELCC kumasu we-Neo-Adjuvant

I-European Lung Cancer Congress (ELCC) yango-2026 yasebenza njengenkundla ebaluleke kakhulu yokwembula idatha eguquguqukayo ku-NSCLC ekhishwa kabusha. Ucwaningo oluningana olwethulwe e-Copenhagen lubeke amabhentshimakhi amasha ahlanganisa ukunakekelwa okujwayelekile kweSigaba 2A kanye nesifo esithuthuke endaweni.

Enye yezingxoxo ezibaluleke kakhulu yayizungeza imikhawulo yomgogodla wendabuko we-“PD-1 inhibitor plus chemotherapy”. Nakuba izifundo ezifana ne-CheckMate 816 kanye ne-KEYNOTE-671 zisungula le nhlanganisela, ingxenye enkulu yeziguli isahluleka ukuzuza i-pCR. Ucwaningo olusha lugxile ekuqiniseni lezi zinhlobo zemithi ngokuphepha.

Ochwepheshe kwa-ELCC 2026 bagqamise ukuthi ikusasa lisezinhlanganisela eziqondene nawe. Lokhu kuhlanganisa ukungeza ama-ejenti anoveli afana namasosha omzimba angama-bispecific noma ukuhlanganisa imithi yokwelapha yendawo efana ne-radiotherapy ukuze kuthuthukiswe ukusebenza kokuzivikela komzimba ngaphambi kokuba ummese uthinte isikhumba.

I-Neo-RISE Lung Study: I-Paradigm Entsha

Isethulo esivelele ku-ELCC 2026 kwakuyidatha yokuqala evela ocwaningweni lwe-Neo-RISE Lung. Lolu cwaningo olusha lwahlola indlela ye-triple-modality: i-immunogenic radiotherapy elandelwa yi-PD-1/VEGF bispecific antibody (ivonescimab) kanye nokwelashwa ngamakhemikhali.

Isizathu salo mklamo sivumelana. I-Radiotherapy idala ukufa kwamangqamuzana e-immunogenic, ikhiphe ama-antigen e-tumor. I-bispecific antibody ibe isivimba izindawo zokuhlola amasosha omzimba ngesikhathi esisodwa ngenkathi ivimbela i-angiogenesis ngokucindezelwa kwe-VEGF. Lokhu "okukodwa-okubili" kuqinisa amasosha omzimba ngempumelelo kunokwelashwa ngamakhemikhali kuphela.

• Izinga Lempendulo Yenhloso (ORR): Ucwaningo lubike i-ORR emangazayo engu-100% eqenjini elihloliwe.
• Impendulo Ephelele Ye-Pathological (pCR): Amanani afinyelele ku-55.1%, aphezulu kakhulu kunezilawuli zomlando ezingu-~24%.
• Impendulo Enkulu Ye-Pathological (MPR): Kutholwe ku-79.3% weziguli.
• Ukwehlisa: U-88.2% weziguli wabhekana nokwehla kwesimila, okwenza kube lula ukuhlinzwa kokuhlinzwa.

Okubi kakhulu ukuthi zonke iziguli eziye zahlinzwa zathola ukukhishwa kabusha ngo-R0, okusho ukuthi awekho amaseli omdlavuza ashiywe emaphethelweni. Le datha iphakamisa ukuthi ezigulini zeSigaba 2A, ukwengeza i-radiotherapy kanye ne-biologics eqondiswe kabili kungaba indinganiso entsha yezici ezinobungozi obukhulu.

KEYNOTE-671 Idatha Yesikhathi Eside: Amandla e-Perioperative Immunotherapy

Elinye itshe lesisekelo le-ELCC yango-2026 kwaba ukuhlaziya okubuyekeziwe kwesikhathi eside kwesivivinyo se-KEYNOTE-671. Lolu cwaningo lweSigaba sesi-3 luhlole i-pembrolizumab ehlanganiswe ne-chemotherapy njengokwelashwa kwe-neo-adjuvant, kwalandelwa i-adjuvant pembrolizumab monotherapy.

Okutholakele kwakamuva, okusekelwe ezinyangeni ezingaphezu kwezingu-60 zokulandelela, kuqinisekisile ukuthi inzuzo ye-perioperative immunotherapy ihlala isikhathi eside. Okubalulekile, idatha yahlukanisa iziguli ngokusabela kwazo kwe-pathological, enikeza imininingwane engaqondakali kodokotela abelapha isifo se-Stage 2A.

Ngisho neziguli ezingazange zifinyelele impendulo ephelele ye-pathological (non-pCR) zithole izinzuzo ezibalulekile zokusinda ngaphandle kwemicimbi (EFS). Isilinganiso sengozi ye-EFS eqenjini elingelona i-pCR sasingu-0.69, okubonisa ukuncipha kwe-31% engozini yokuphindaphinda noma ukufa uma kuqhathaniswa ne-placebo.

Kulabo abazuze i-pCR, imiphumela yayingavamile, ngezinga le-EFS leminyaka emi-5 lama-81%. Lokhu kuqinisa umqondo wokuthi nakuba i-pCR iwumaka onamandla, umphumela wesistimu we-immunotherapy uvikela iziguli kungakhathaliseki ukujula kokusabela kwe-pathological.

Izindlela zokwelapha ezihlosiwe ze-Driver-Mutated Stage 2A Umdlavuza wamaphaphu

Akuwona wonke umdlavuza wamaphaphu weSigaba 2A oqhutshwa izindlela ezifanayo. Cishe u-15-20% weziguli zaseNtshonalanga kanye kufika ku-50% weziguli zase-Asia zifukamela ukuguqulwa komshayeli njenge-EGFR noma i-ALK. Kulaba bantu, i-immunotherapy iyodwa ingase ingabi isu elilungile le-neo-adjuvant.

I-ELCC yango-2026 ihlinzeke ngezibuyekezo ezibucayi ekwelashweni okuhlosiwe esimisweni se-perioperative. Uhlolo lwe-ADAURA ngaphambilini lusungule i-osimertinib njengezinga lokwelashwa kwe-adjuvant ku-NSCLC eguqulwe i-EGFR. Idatha entsha manje iphusha lawa ma-ejenti endaweni ye-neo-adjuvant.

Ukuguqulwa kwe-EGFR kanye ne-TOP Study Insights

Nakuba ucwaningo lwe-TOP ngokuyinhloko lugxile esifweni esithuthukisiwe se-metastatic, imithelela yaso yokwelashwa kwesigaba sangaphambi kwesikhathi ijulile. Ucwaningo luphenye i-osimertinib ehlanganiswe ne-chemotherapy ngokumelene ne-osimertinib yodwa ezigulini ezinokuguqulwa kwe-EGFR kanye nokuguqulwa kwe-TP53 okufanayo.

Ukuguqulwa okuhlangene kwe-TP53 kwaziwa ngokunikeza ukumelana ne-EGFR tyrosine kinase inhibitors (TKIs). Ucwaningo lwe-TOP lubonise ukuthi ukungeza i-chemotherapy ku-osimertinib kuphindwe kabili i-progression-free survival (PFS) kuleli qembu elincane elinobungozi obukhulu. Lokhu kuphakamisa ukuthi ezigulini zeSigaba 2A ezinokuguqulwa okuhlangene kwe-EGFR/TP53, indlela yokuhlanganiswa ingase idingeke ngisho nasesimweni sokwelapha.

Odokotela manje baphikisana ngokuthi kufanele bathathe i-chemo-immunotherapy noma inhlanganisela ye-chemo-TKI yokwelashwa kwe-neo-adjuvant kubantu abanomshayeli. Ukuvumelana kuqhubekela ezinqumweni eziqondiswa amangqamuzana kunendlela eyodwa yokwelashwa kwe-immunotherapy.

I-ALK Positive Disease: I-ALINA Study Impact

Ezigulini ezinokuhlelwa kabusha kwe-ALK, ucwaningo lwe-ALINA luguqule umdlalo. Kubonise ukuthi i-adjuvant alectinib ithuthukisa kakhulu i-DFS uma iqhathaniswa ne-chemotherapy-based chemotherapy. Nakuba idatha ye-neo-adjuvant ikhulile kancane kunedatha ye-adjuvant, ukusebenza kahle kwe-alectinib kumathumba anciphayo ngaphambi kokuhlinzwa kuyaphenywa ngenkuthalo.

Ngo-2026, kugxilwe ekunqumeni isikhathi esifanele sokwelashwa okuqondiwe. Ingabe kufanele inikezwe kuphela ngemva kokuhlinzwa, noma kufanele yamukelwe indlela “yesemishi” (neo-adjuvant + adjuvant)? Izinkomba zakuqala ziphakamisa ukuthi ukwelashwa okuqondiswe ngaphambi kokuhlinzwa kungasiza ukuhlinzwa okungatheni, kulondoloze ukusebenza kwamaphaphu ezigulini zeSigaba 2A.

Ukuhlaziywa Okuqhathaniswayo Kwezindlela Zokwelapha

Ukukhetha ilungelo isigaba 2a ukwelashwa komdlavuza wamaphaphu kudinga ukukala izinzuzo nezingozi zezindlela ezihlukahlukene. Ithebula elilandelayo liqhathanisa amasu ahamba phambili okukhulunywe ngawo e-ELCC 2026.

Lesi siqhathaniso sigcizelela ukuthi “usayizi owodwa awulingani konke.” Ukuba khona kwezimpawu zofuzo ezithile noma inqwaba yesimila kunganquma ukuthi isiguli sizuza kakhulu yini ku-chemo-immunotherapy ejwayelekile, uhlobo lokuhlola oluqinisiwe, noma ama-agent ahlosiwe.

Izinzuzo Nezimbi Zezindlela Ze-Neo-Adjuvant

Ukwamukela i-neo-adjuvant therapy yomdlavuza wamaphaphu weSigaba 2A kunikeza izinzuzo ezihlukile kodwa futhi kwethula izinselelo ezintsha okufanele ziphathwe ngamathimba ezinhlaka eziningi.

• Izinzuzo:
  • Ukulawulwa Kwesistimu Kwasekuqaleni: Yelapha i-micrometastase ngokushesha, inciphisa ingozi yokuphinda okukude.
  • Ukuhlola Ukuzwela Kwe-Vivo: Ivumela odokotela ukuthi babone ukuthi isimila siyashwabana, sinikeze ulwazi lokubikezela.
  • Ukusebenziseka Kabusha Okuthuthukisiwe: Ingakwazi ukwehlisa izimila, iguqule amakesi akhiphekayo asemngceleni ukuze asule ukuhlinza kuka-R0.
  • Ukuthobela Okuphezulu: Iziguli zibekezelela ukwelashwa kwe-systemic kangcono ngaphambi kokuhlinzwa kunesikhathi sokululama.
• Ububi:
  • Ukubambezeleka Ekuhlinzeni: Ukwelashwa kuthatha amasonto, okungase kubangele ukukhathazeka noma ukukhula okungenzeka ezimeni ezinolaka ezingandile.
  • Inkimbinkimbi Yokuhlinzwa: Ukuvuvukala noma i-fibrosis ebangelwa ukwelashwa ngezinye izikhathi kungenza ukuhlukaniswa kube nzima kakhulu kodokotela abahlinzayo.
  • Izingozi Zobuthi: Izehlakalo ezimbi ezihlobene namasosha omzimba (i-irAEs) zingenzeka ngaphambi kokuhlinzwa, okungase kube nzima ukubulawa kwezinzwa noma ukuphulukiswa kwesilonda.

Ngaphandle kwalezi zinselelo, ubufakazi obuqand’ ikhanda obusuka ku-2026 busekela inzuzo yonke yamasu e-neo-adjuvant ezigulini ezifanelekile zeSigaba 2A. Okubalulekile kusekukhethweni kwesiguli ngokucophelela kanye nokuxhumana okuqinile kwemikhakha eminingi.

Isinyathelo Ngesinyathelo Umhlahlandlela Wokuphatha Isigaba 2A Sesimanje

Ukuzulazula ohambweni lokwelashwa lomdlavuza wamaphaphu weSigaba 2A ngo-2026 kuhilela inqubo ehlelekile, enemikhakha eminingi. Nakhu ukugeleza komsebenzi okuvamile okusekelwe kuzinqubo ezihamba phambili zamanje.

• Isinyathelo 1: Isiteji Esiphelele kanye Nemininingwane Yamamolekyuli
  
  Ngaphambi kwanoma yisiphi isinqumo sokwelashwa, iziguli zithola izikena ze-PET-CT kanye ne-MRI yobuchopho ukuze kukhishwe i-metastasis ekude. Okubaluleke kakhulu, i-tissue biopsy kufanele ihlolelwe i-EGFR, ALK, ROS1, kanye nenkulumo ye-PD-L1. Lesi sinyathelo sinquma ukuthi isiguli siyangena yini ku-immunotherapy noma endleleni yokwelapha eqondiwe.
• Isinyathelo sesi-2: Ukubuyekezwa kwethimba le-Multidisciplinary (MDT).
  
  Ithimba elihlanganisa odokotela abahlinza isifuba, izazi zezokwelapha, izazi ze-radiation oncologists, kanye nodokotela bezifo babuyekeza icala. Bahlola ukuhleleka kabusha futhi baxoxe ngezinzuzo ezingaba khona zokwelashwa kwe-neo-adjuvant ngokumelene nokuhlinzwa kwangaphambili ngokusekelwe kudatha yakamuva ye-ELCC.
• Isinyathelo sesi-3: Ukuqaliswa kwe-Neo-Adjuvant Therapy
  
  Uma kufaneleka, isiguli siqala uhlobo olukhethiwe. Ezigulini ezingenawo umshayeli, lokhu ngokuvamile imijikelezo engu-3-4 ye-chemotherapy-doublet chemotherapy kanye ne-PD-1/PD-L1 inhibitor. Ezimweni ezisengozini enkulu, izinhlolo zokwelashwa ezibandakanya amasosha omzimba ahlukene noma i-radiotherapy ingase inikezwe.
• Isinyathelo sesi-4: Ukubuyisela kabusha kanye Nokuhlela Ukuhlinzwa
  
  Ngemva kokuqeda imijikelezo ye-neo-adjuvant, ukuphindaphinda kwesithombe kwenziwa ukuze kuhlolwe impendulo. Uma lesi sifo sizinzile noma siphendula, ukuhlinzwa kuhlelwe ngokuvamile amasonto angu-3-6 ngemva komthamo wokugcina we-immunotherapy ukuze kuvunyelwe ukubuyiswa komzimba.
• Isinyathelo sesi-5: Ukukhishwa kabusha kokuhlinzwa kanye nokuhlolwa kwe-Pathological
  
  Udokotela ohlinzayo wenza i-lobectomy noma i-segmentectomy nge-lymph node dissection. Udokotela wezifo uhlola isampula ukuze anqume I-Major Pathological Response (MPR) noma I-Pathological Complete Response (pCR), eqondisa ukwelashwa okwengeziwe.
• Isinyathelo sesi-6: Ukuhlanganiswa Kwe-Adjuvant
  
  Ngokuya ngohlelo lokuqala kanye nokutholakala kwe-pathological, iziguli zingase ziqhubeke ne-adjuvant immunotherapy (isb., i-pembrolizumab) kuze kube unyaka noma zishintshele ekwelapheni okuhlosiwe (isb., i-osimertinib) uma kutholakala ukuguqulwa. Le ndlela "ye-perioperative" iqinisekisa ukuvikelwa okuqhubekayo ekuphindeni.

Iqhaza Lokuqapha Izifo Ezinsalela Ezincane (MRD).

Ithuluzi elivelayo ngo-2026 ukusetshenziswa kwe-circulating tumor DNA (ctDNA) ukuqapha Izifo Ezincane Ezisele (MRD). Lobu buchwepheshe buthola amanani amancane e-DNA yomdlavuza egazini leyo imaging ayikwazi ukubonwa.

Ucwaningo olwethulwe ezingqungqutheleni zakamuva luphakamisa ukuthi ukusula i-ctDNA phakathi nokwelashwa kwe-neo-adjuvant kuwukubikezela okunamandla kokusinda kwesikhathi eside. Ngokuphambene, i-ctDNA eqhubekayo ngemva kokuhlinzwa ingase ihlonze iziguli ezidinga ukwelashwa okuthuthukisiwe kwe-adjuvant. Nakuba kungakabi yisibopho emhlabeni wonke, ukuqapha kwe-MRD ngokushesha kuba ingxenye evamile ye-oncology enembile yeSigaba 2A somdlavuza wamaphaphu.

Isibonelo, idatha ye-cadonilimab (i-PD-1/CTLA-4 bispecific antibody) ibonise ukuthi iziguli ezithole imvume ye-ctDNA zazinokusinda isikhathi eside ngaphandle kokuqhubekela phambili. Le luphu yempendulo yamangqamuzana ivumela ukulungiswa kokwelashwa okuguquguqukayo, ukusuka kumaphrothokholi esikhathi esinqunyiwe.

Ukucatshangelwa Komtholampilo Kwabantu Abakhethekile

Ukwelapha Isigaba 2A somdlavuza wamaphaphu akufani kuzo zonke izinhlobo zabantu. Izibalo ezithile zidinga izindlela eziklanyelwe ukulinganisa ukusebenza kahle nokuphepha.

Iziguli Ezikhulile Nalezo Ezinesimo Esingesihle Sokusebenza

Abantu abadala asebekhulile noma iziguli ezine-commorbidities zivame ukulwa nobuthi bomthamo ogcwele we-chemo-immunotherapy. Uhlolo lwe-ETOP ADEPPT kanye nocwaningo olufanayo luhlole izindlela zokwelapha eziqondiswe yi-ejenti eyodwa kulawa maqembu.

Ngo-2026, inkambiso ibheke “ekwehleni” kweziguli ezibuthaka. Lokhu kungase kuhilele ukusebenzisa i-immunotherapy monotherapy uma isisho se-PD-L1 siphezulu, noma ukukhetha ama-ejenti aqondiwe uma kukhona ukuguqulwa komshayeli, ukugwema imiphumela emibi enzima ye-platinamu chemotherapy. Umgomo uhlala ukwelapha, kodwa indlela iyalungiswa ukuze kuqinisekiswe ukuthi isiguli singakwazi ukuqeda ukwelashwa.

Iziguli ezine-Brain Metastases

Ngenkathi i-Stage 2A isho ukuthi akukho ukusabalala okude, ama-metastases obuchopho obusebenzelana nemimoya ngezinye izikhathi angatholakala ekuhlolweni okunemininingwane. Ama-TKI esizukulwane esisha afana ne-osimertinib ne-alectinib anokungena kwesistimu yezinzwa emaphakathi (CNS).

Ezigulini ezinemetastase yobuchopho elinganiselwe etholwe ngesikhathi sokuqalwa, ukwelashwa okuhleliwe okunezidakamizwa ezisebenza ku-CNS kuvame ukubekwa phambili ngaphambi kokwelashwa kobuchopho bendawo. Ucwaningo lwe-ARTS kanye ne-ALINA luqinise ukuzethemba ekwelapheni isifo sesigaba sokuqala ngama-ejenti avikela ubuchopho, okunciphisa isidingo semisebe ye-cranial ehlaselayo kwezinye izimo.

Izikhombisi-ndlela zesikhathi esizayo kanye nocwaningo oluqhubekayo

Indawo ye isigaba 2a ukwelashwa komdlavuza wamaphaphu inamandla. Njengoba sidlulela ku-2026, izindawo ezimbalwa zocwaningo zithembisa ukuqhubeka nokwenza ngcono imiphumela. Ukuhlanganiswa kobuhlakani bokwenziwa kuma-radiomics kusiza ukubikezela ukuthi yiziphi iziguli ezizosabela ekwelashweni kwe-neo-adjuvant ngaphambi kokuthi ngisho kuqale ukwelashwa.

Ukwengeza, ukuthuthukiswa kwama-conjugates esizukulwane esilandelayo se-antibody-drug conjugates (ADCs) kuvula iminyango emisha. Izivivinyo ezibandakanya ama-ADC aqondiswe ku-HER3 kanye nama-ejenti aqondiswe ku-TROP2 abonisa isithembiso esimweni se-neo-adjuvant, okungenzeka sinikeze izinketho ezigulini ezingaphenduli ekwelashweni kokuzivikela okujwayelekile.

Umqondo "wokwelashwa okuphelele kwe-neoadjuvant" nawo uyakhula. Le ndlela yokwelapha iqeda ngokuphelele ukwelashwa kwe-adjuvant, ukuletha konke ukwelashwa okuhlelekile ngaphambi kokuhlinzwa. Idatha yangaphambi kwesikhathi iphakamisa ukuthi lokhu kungenza uhambo lwesiguli lube lula futhi kuthuthukise ukuthobela imithetho, nakuba idatha yokusinda yesikhathi eside isakhula.

Ukubaluleka Kwezilingo Zomtholampilo

Uma kubhekwa ukuvela ngokushesha kwamazinga okwelashwa, ukubhaliswa ezivivinyweni zomtholampilo kukhuthazwa kakhulu ezigulini zeSigaba 2A. Izivivinyo ezifana ne-Galaxy-L-01, ukuphenya i-garsorasib ehlanganiswe ne-anlotinib yokuguqulwa kwe-KRAS G12C, inikeza ukufinyelela ekwelashweni kwesimanje ngaphambi kokuba kutholakale kabanzi.

Ukubamba iqhaza kulezi zifundo akuzuzisi nje isiguli ngasinye kuphela kodwa kuphinde kufake isandla kusisekelo solwazi lomhlaba wonke, kusheshise ukutholakala kwamakhambi. Odokotela bayanxuswa ukuthi baxoxisane ngokufanelekela ukuqulwa kwecala nazo zonke iziguli ezifanele ekuxilongeni.

Isiphetho: Inkathi Entsha Yethemba Yesigaba 2A Umdlavuza Wamaphaphu

Unyaka ka-2026 uphawula ushintsho oluqinisekile ekuphathweni komdlavuza wamaphaphu we-Stage 2A ongewona omncane. Zahamba izinsuku lapho ukuhlinzwa kwakuyimpendulo yodwa. Namuhla, isigaba 2a ukwelashwa komdlavuza wamaphaphu kuwumzamo oyinkimbinkimbi, osebenzisa izindlela eziningi ohlanganisa ukunemba kokwelashwa okuhlosiwe, amandla e-immunotherapy, kanye nesikhathi samasu sokungenelela kwe-neo-adjuvant.

Idatha evela ku-ELCC yango-2026, ikakhulukazi mayelana nocwaningo lwe-Neo-RISE Lung kanye nemiphumela yesikhathi eside ye-KEYNOTE-671, iqinisekisa ukuthi singafinyelela amazinga okwelapha aphezulu kunangaphambili. Ngokwenza ukwelashwa okuqondene nawe okusekelwe kumaphrofayili amangqamuzana kanye nokwesekwa kwenhlanganisela yenoveli efana ne-bispecific antibodies kanye ne-immunogenic radiotherapy, odokotela baguqula izimo ezike zaba nzima zibe yizindaba zempumelelo.

Ezigulini nasemindenini, lokhu kusho ikusasa elinezinketho eziningi, amathuba okuphila angcono, kanye nezinga lempilo elithuthukisiwe. Njengoba ucwaningo luqhubeka nokuveza ubunkimbinkimbi bebhayoloji yomdlavuza wamaphaphu, umkhondo ukhomba ezindleleni ezisebenza kahle kakhulu, ezinobuthi obuncane, kanye nezindlela zokunakekelwa komuntu siqu kakhulu. Ukusebenzisana phakathi kodokotela abahlinzayo, ongoti be-oncologists, nabacwaningi kusalokhu kuyinsika yale nqubekelaphambili, ukuqinisekisa ukuthi sonke isiguli seSigaba 2A sithola ithuba elingcono kakhulu lokwelashwa.